http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017070441-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0ca0841c52dc980c3f201762d410f79b |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C40B40-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate | 2016-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_480b482b193518b01ec64eb54054914c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eaf95d157e96a6e280f956217c40abd0 |
| publicationDate | 2017-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2017070441-A1 |
| titleOfInvention | Identifying and treating cancer patients who are suitable for a targeted therapy using an hdac6 inhibitor |
| abstract | It has been discovered that proliferation of inflammatory breast cancer (IBC) cells can be inhibited by inhibiting the function of histone deacetylase 6 (HDAC6). Advantageously, such functional inhibition is accomplished by administration of a therapeutically effective dose of Ricolinostat (ACY1215) to a patient in whom IBC cells are proliferating. In further accordance with the invention, it is possible to predict the responsiveness of a particular patient with cancer (particularly breast cancer, and most specifically inflammatory breast cancer) to administration of an HDSC6 inhibitor. This is accomplished by acquiring mRNA gene expression profiles of a biopsy sample of the patient's tumor tissue. The processed gene expression profiles of the patient are then integrated into a gene expression database and are then normalized across the entire database. Then, the normalized gene expression profiles are input to an algorithm. An HDAC6 signature characteristic of the patient's tumor type is also input to the algorithm, and the output of the algorithm makes it possible to evaluate the responsiveness of the patient's tumor to administration of HDAC6 inhibitor. Advantageously, the gene expression profiles are acquired using standard RNA-Seq technology or microarray and the gene expression database is The Cancer Genome Atlas ("TCGA"). |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023094365-A1 |
| priorityDate | 2015-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 58.